2Seventy Bio

2Seventy Bio FCF Growth

Delisted

The Year-over-Year Free Cash Flow Growth of 2Seventy Bio (TSVT) as of Nov 5, 2026 is 52.58 %. In the previous year, Year-over-Year Free Cash Flow Growth was 30.48 % — a change of 72.47% (higher).

FCF Growth

52.58 %

YoY

72.47%

Last updated:

Year-over-Year Free Cash Flow Growth of 2Seventy Bio is 2024 52.58 % . Year-over-Year Free Cash Flow Growth of 2Seventy Bio was 2023 30.48 % . It decreases by 72.47% higher compared to the previous year.

The 2Seventy Bio FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-35.87 USD
Jan 1, 2020
66.36 USD
Jan 1, 2021
-151.64 USD
Jan 1, 2022
-14.72 USD
Jan 1, 2023
30.48 USD
Jan 1, 2024
52.58 USD
The 2Seventy Bio FCF Growth history
YEARFCF GrowthYoY
52.58 %+72.47%
30.48 %-307.03%
-14.72 %-90.29%
-151.64 %-328.50%
66.36 %-285.01%
-35.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

2Seventy Bio Stock analysis

What does 2Seventy Bio do? 2seventy Bio, Inc. generates revenue through its cell and gene therapy programs, including SC-DARIC33 for pediatric relapsed and refractory acute myeloid leukemia and bbT369 for B-cell non-Hodgkin lymphoma. The company collaborates with Bristol Myers Squibb to deliver Abecma for multiple myeloma patients in the U.S., leveraging its T cell engineering and lentiviral vector technologies. Its clinical and preclinical programs, such as bbT4015 targeting MUC16, form the core of its product pipeline. The company focuses on developing targeted cellular therapies for cancer patients, with Bristol Myers Squibb as a key partner in commercializing Abecma. 2seventy Bio, Inc. operates in the biopharmaceutical sector, targeting patients with specific cancer types through its advanced therapies. Its products are developed using proprietary T cell engineering and lentiviral vector delivery systems. The company's revenue streams include clinical trial partnerships and potential future commercial sales of its therapies. Bristol Myers Squibb supports the U.S. distribution of Abecma, a key product in its portfolio. 2Seventy Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2Seventy Bio stock

Year-over-Year Free Cash Flow Growth of 2Seventy Bio is 52.58 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth 2Seventy Bio since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's 2Seventy Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — 2Seventy Bio

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — 2Seventy Bio